Tags

Type your tag names separated by a space and hit enter

In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
J Control Release. 2006 Aug 28; 114(2):153-62.JC

Abstract

The specific aims of this investigation were (1) to show that conventional and PEGylated liposomes can penetrate cancer cells in vitro and in vivo; (2) to demonstrate that liposomes can be successfully used both for cytoplasmic and nuclear delivery of therapeutics, including anticancer drugs and antisense oligonucleotides; (3) to examine the specific activity of anticancer drugs and nucleotides delivered inside tumor cells by PEGylated liposomes; and (4) to confirm that simultaneous inhibition of pump and nonpump cellular resistance by liposomal ASO can substantially enhance the antitumor activity of traditional well established anticancer drugs in mice bearing xenografts of human multidrug resistant ovarian carcinoma. Experimental results show that PEGylated liposomes are capable of penetrating directly into tumor cells after systemic administration in vivo and do successfully provide cytoplasmic and nuclear delivery of encapsulated anticancer drug (doxorubicin, DOX) and antisense oligonucleotides (ASO). Encapsulation of DOX and ASO into liposomes substantially increased their specific activity. Simultaneous suppression of pump and nonpump resistance dramatically enhanced the ability of DOX for inducing apoptosis leading to higher in vitro cytotoxicity and in vivo antitumor activity.

Authors+Show Affiliations

Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

16889867

Citation

Pakunlu, Refika I., et al. "In Vitro and in Vivo Intracellular Liposomal Delivery of Antisense Oligonucleotides and Anticancer Drug." Journal of Controlled Release : Official Journal of the Controlled Release Society, vol. 114, no. 2, 2006, pp. 153-62.
Pakunlu RI, Wang Y, Saad M, et al. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release. 2006;114(2):153-62.
Pakunlu, R. I., Wang, Y., Saad, M., Khandare, J. J., Starovoytov, V., & Minko, T. (2006). In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. Journal of Controlled Release : Official Journal of the Controlled Release Society, 114(2), 153-62.
Pakunlu RI, et al. In Vitro and in Vivo Intracellular Liposomal Delivery of Antisense Oligonucleotides and Anticancer Drug. J Control Release. 2006 Aug 28;114(2):153-62. PubMed PMID: 16889867.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. AU - Pakunlu,Refika I, AU - Wang,Yang, AU - Saad,Maha, AU - Khandare,Jayant J, AU - Starovoytov,Valentin, AU - Minko,Tamara, Y1 - 2006/06/15/ PY - 2006/05/31/accepted PY - 2006/8/8/pubmed PY - 2006/10/20/medline PY - 2006/8/8/entrez SP - 153 EP - 62 JF - Journal of controlled release : official journal of the Controlled Release Society JO - J Control Release VL - 114 IS - 2 N2 - The specific aims of this investigation were (1) to show that conventional and PEGylated liposomes can penetrate cancer cells in vitro and in vivo; (2) to demonstrate that liposomes can be successfully used both for cytoplasmic and nuclear delivery of therapeutics, including anticancer drugs and antisense oligonucleotides; (3) to examine the specific activity of anticancer drugs and nucleotides delivered inside tumor cells by PEGylated liposomes; and (4) to confirm that simultaneous inhibition of pump and nonpump cellular resistance by liposomal ASO can substantially enhance the antitumor activity of traditional well established anticancer drugs in mice bearing xenografts of human multidrug resistant ovarian carcinoma. Experimental results show that PEGylated liposomes are capable of penetrating directly into tumor cells after systemic administration in vivo and do successfully provide cytoplasmic and nuclear delivery of encapsulated anticancer drug (doxorubicin, DOX) and antisense oligonucleotides (ASO). Encapsulation of DOX and ASO into liposomes substantially increased their specific activity. Simultaneous suppression of pump and nonpump resistance dramatically enhanced the ability of DOX for inducing apoptosis leading to higher in vitro cytotoxicity and in vivo antitumor activity. SN - 0168-3659 UR - https://www.unboundmedicine.com/medline/citation/16889867/In_vitro_and_in_vivo_intracellular_liposomal_delivery_of_antisense_oligonucleotides_and_anticancer_drug_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-3659(06)00257-4 DB - PRIME DP - Unbound Medicine ER -